Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Velcade on Bone Tissue in Myelomatosis
NCT00436059Phase 2Completed
- Sponsor
- Vejle Hospital
- Start
- Feb 2007
- Primary completion
- Jul 2009
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bortezomib in multiple myeloma (MM), sponsored by Vejle Hospital. Primary endpoint: Changes in bone markers during treatment. Started Feb 2007; status: completed.
02
Drugs
bortezomib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT00436059.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00436059.